The variable association between expression and methylation of estrogen receptors and the survival of patients with different tumors

Clinical and Translational Medicine

卷:10

Junhong Hu¹  Congzhu Li²  Shan Jiang³  Yinhua Liu⁴  Hongjin Chen⁵  Haojun Xu⁵  Hongping Xia⁵  Chao Hu⁵ 

[1] Department of General Surgery Huaihe Hospital of Henan University Kaifeng China;

[2] Department of Gynecologic Oncology Cancer Hospital of Shantou University Medical College Shantou Guangdong China;

[3] Department of Oncology The First Affiliated Hospital of Chongqing Medical University Chongqing China;

[4] Department of Pathology The First Affiliated Yijishan Hospital of Wannan Medical College & Key Laboratory of Non‐coding RNA Transformation Research of Anhui Higher Education Institutes Wannan Medical College Wuhu China;

[5] State Key Laboratory of Reproductive Medicine & Department of Pathology in the School of Basic Medical Sciences & The Affiliated Sir Run Run Hospital & Key Laboratory of Antibody Technique of National Health Commission Nanjing Medical University Nanjing China;

关键词: estrogen receptor;    methylation;    mRNA;    protein;    survival;   

DOI  :  10.1002/ctm2.49

来源: DOAJ

【 摘 要 】

Abstract Background Estrogen receptor (ER) is essential in reproductive development and is also the primary driver of breast cancers. Deregulation of ER may also be involved in tumorigenesis of other organs. To understand the role of ER in different tumor types, pan‐cancer analysis of estrogen receptor alpha (ESR1) and estrogen receptor beta (ESR2) in various tumors and association with patients' survival were conducted using The Cancer Genome Atlas (TCGA) data. Results Gene methylation level was evaluated by the mean methylation level of CpG sites in the promoter region. The significant different DNA methylation between tumor and healthy tissues was shown in 10 tumor types for ESR1 and eight tumor types for ESR2. The methylation pattern was also varied across different TCGA tumors. The pan‐cancer analysis showed significantly different mRNA expression of ESR1 in nine tumor types and ESR2 in four tumor types. Survival analysis showed that the effects of ERs expression on survival are diverse in different tumors. The expression of ERs was associated with tumor molecular subtypes and various clinical characteristics. ER correlated genes were mainly enriched in cancer and immune‐related pathways. Conclusions Our pan‐cancer analysis data indicated that ERs might be significantly associated with carcinogenesis and progression of some tumors, which may be potential therapeutic targets and prognosis biomarkers.

【 授权许可】

Unknown